Genetically engineered t cell and application thereof
OwnerZonghai LI, Xingliang GUOinventors
Life of this patent
Estimating the term…
Abstract
Provided are a genetically engineered T cell and a pharmaceutical composition using the same. The T cell has an endogenous T cell receptor (TCR) that is inactivated or inactive, comprises encoding of an exogenous receptor bindable to a target antigen, and contains an open reading frame regulated by the exogenous receptor. When the exogenous receptor binds to the target antigen, expression of the open reading frame can be initiated. The T cell has a killing effect on tumor cells and has reduced side effects and enhanced safety.
Claims34
A genetically engineered T cell, wherein the endogenous T cell receptor (TCR) in said T cell is inactivated or inactive;
- and
- said T cell comprises an open reading frame, the open reading frame encodes an exogenous receptor capable of binding to a target antigen and is regulated by the exogenous receptor, and when the exogenous receptor binds to the target antigen, the expression of the open reading frame can be initiated.
An expression construct, comprising:
- the expression cassette of the exogenous receptor that can bind to the target antigen and trigger the activation of CD3 signal of any one of the preceding claims linked together with the expression cassette of the open reading frame operably connected to the promoter directly or through a linker molecule.
Dependencies are inferred from the claim text.